Latest From Theraclion SAS
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved BaroNova's TransPyloric Shuttle and its delivery system to treat obesity. It also cleared NeuroSigma’s Monarch external trigeminal nerve stimulation system, making it the first FDA-approved device for treating attention deficit hyperactivity disorder.
A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.
US FDA has approved the University of Virgina's plan to evaluate a therapy combining Theraclion's high intensity focused ultrasound with Merck's Keytruda (pembrolizumab) immunotherapy drug for the treatment of metastatic breast cancer.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.
- Medical Devices
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Theraclion SAS
- Senior Management
Ismaël Nujurally , MD, CEO
François Lacoste, CSO
David Del Bourgo , Dir., Bus. Dev.
- Contact Info
Phone: (33) 1 53 10 30 90
29 rue du Faubourg Saint Jacques
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.